Abstracts Archive - Page 826 of 2425 - ACR Meeting Abstracts

Abstract Number: 1014 • 2019 ACR/ARP Annual Meeting
Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients
Siba Raychaudhuri¹ and Smritikana Raychaudhuri ², ¹UC Davis School of Medicine, Sacramento, CA, ²UC Davis School of Medicine, Davis, CA
Background/Purpose: Here we hypothesized that (i) IL-23/IL-23R system more specifically the specific IL-23p19 subunit mediated signaling system regulates expansion/maintenance and functional maturation in respect to…
Abstract Number: 1015 • 2019 ACR/ARP Annual Meeting
Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals
Emma Van Lieshout¹, Dennisse Bonilla ², Zahi Touma ³, Arthur Bookman ⁴, Linda Hiraki ⁵, Zareen Ahmad ⁶, Sindhu Johnson ⁷, Earl D. Silverman ⁸ and Joan Wither ⁹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, Canada, ⁴University Health Network - Toronto Western Hospital, Toronto, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, ⁶Mount Sinai Hospital, Toronto, Canada, ⁷Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁹University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) including Sjogren’s Disease (SjD), Systemic Sclerosis (SSc) and Systemic Lupus Erythematosus (SLE) are characterized by the production of anti-nuclear…
Abstract Number: 1016 • 2019 ACR/ARP Annual Meeting
Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis
Wei Liu¹, Yuanhao Wu ¹ and Wenjia Zhao ¹, ¹First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a common autoimmune disease. The occurrence and development of SLE is a result of multiple factors, but its exact…
Abstract Number: 1017 • 2019 ACR/ARP Annual Meeting
The Integration of Genetic Data, Molecular Pathway Analysis and Differential Expression to Delineate the Impact of Ancestral Differences on Lupus
Katherine Owen¹, Bryce Aidukaitis ¹, Adam Labonte ¹, Michelle Catalina ¹, Prathyusha Bachali ¹, Nicholas Geraci ², Miranda Marion ³, Hannah Ainsworth ⁴, kip Zimmerman ³, Timothy Howard ⁴, Carl Langefeld ⁴, Peter Lipsky ² and Amrie Grammer ⁵, ¹AMPEL Biosolutions and the RILITE research institute, Charlottesville, VA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Wake Forest School of Medicine, Winston-Salem, NC, ⁴Wake Forest School of Medicine, Winston-Salem, ⁵AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disorder with a prominent genetic component. Evidence has shown that individuals of African-Ancestry (AA) experience the…
Abstract Number: 1018 • 2019 ACR/ARP Annual Meeting
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, Chaim Putterman ⁴, Nir Hacohen ⁵, Arnon Arazi ⁵, Celine Berthier ⁶, Deepak Rao ⁷, Michael Brenner ⁸, David Wofsy ⁹, Anne Davidson ¹⁰, Mathias Kretzler ¹¹, David Hildeman ¹², E. Steve Woodle ¹², Betty Diamond ¹⁰, Thomas Tuschl ¹³, Evan Der ¹⁴, Hemant Suryawanshi ¹³, H. Michael Belmont ¹⁵, Peter Izmirly ¹⁶, Robert Clancy ¹⁶, The Accelerating Medicines Partnership ¹⁷ and Michelle Petri ¹⁸, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Broad Institute, Cambridge, ⁶University of Michigan, Ann Arbor, MI, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women’s Hospital:, Boston, ⁹UCSF, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹University of Michigan, Ann Arbor, ¹²University of Cincinnati, Cincinnati, ¹³Rockefeller Research Laboratories, New York, ¹⁴Albert Einstein College of Medicine, New York, ¹⁵New York University School of Medicine, Ney York, ¹⁶New York University School of Medicine, New York, ¹⁷Multiple Organizations, USA, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Compared to Caucasian, African-American ethnicity is associated with a higher risk of developing systemic lupus erythematosus, lupus nephritis, high-risk histological features, resistance to treatment,…
Abstract Number: 1019 • 2019 ACR/ARP Annual Meeting
Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts
Justine Shum¹, Yogita Ghodke-Puranik ², Regine Tipon ², Jessica Dorschner ³, Danielle Vsetecka ³, Shreyasee Amin ⁴, Ashima Makol ⁵, Floranne Ernste ⁴, Thomas Osborn ⁵, Kevin Moder ³, Vaidehi Chowdhary ³, Uma Thanarajasingam ⁶, Vilija Oke ⁷, Iva Gunnarsson ⁷, Agneta Zickert ⁷, Maria Zervou ⁸, Elisabet Svenungsson ⁹, George Goulielmos ⁸ and Timothy Niewold ², ¹NYU School of Medicine, New York, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, ³Mayo Clinic, Rochester, ⁴Mayo Clinic Rochester, Rochester, MN, ⁵Mayo Clinic Minnesota, rochester, MN, ⁶Mayo Clinic, Rochester, MN, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸University of Crete, Crete, Greece, ⁹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Type I interferon (IFN) is an important mediator in the pathogenesis of systemic lupus erythematosus. Serum type I IFN levels clearly vary between SLE…
Abstract Number: 1020 • 2019 ACR/ARP Annual Meeting
NLRP12 Regulates Interferon-α Expression and Is a Biomarker for Disease Activity of Systemic Lupus Erythematosus
Ming-Han Chen¹, Yen-Po Tsao ¹ and Szu-Ting Chen ², ¹Division of Allergy, Immunology & Rheumatology/Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), ²Institutes of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan (Republic of China)
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune disease with diverse etiological factors. It was well recognized that interferon (IFN) signature did the perpetration…
Abstract Number: 1021 • 2019 ACR/ARP Annual Meeting
Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice
Michelle Huang¹, Ariel Stock ², Elise Mike ², Roland Kolbeck ³ and Chaim Putterman ⁴, ¹Albert Einstein College of Medicine, Bronx, ²Albert Einstein College of Medicine, Bronx, NY, ³MedImmune, Gaithersburg, MD, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: Many systemic lupus erythematosus patients display a type I interferon (IFN) signature, and IFNα levels and gene signatures have been positively correlated with disease…
Abstract Number: 1022 • 2019 ACR/ARP Annual Meeting
Single Cell Transcriptome Analysis of Circulating Plasmacytoid Dendritic Cells and Switched Memory B-cells in SLE Patients Reveals Transcriptional Subsets Within the Classical Cell Lineages
Amrutesh Puranik¹, Yogita Ghodke-Puranik ², Regine Tipon ², Mark Jensen ¹, Auroni Gupta ³, Jacqueline Paredes ³, Uma Sankaramanchi ⁴, Ilona Nln ³, Amit Saxena ⁵, H. Michael Belmont ⁶, Peter Izmirly ⁷, Robert Clancy ⁷, Jill Buyon ⁵ and Timothy Niewold ², ¹Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, ³Colton Center for Autoimmunity, NYU School of Medicine, ny, ⁴Colton Center for Autoimmunity, NYU Langone Medical Center, NY, ⁵New York University School of Medicine, New York, NY, ⁶New York University School of Medicine, Ney York, ⁷New York University School of Medicine, New York
Background/Purpose: Both plasmacytoid dendritic cells (pDCs) and switched memory B cells (SMBCs) are considered to be key effector cells in systemic lupus erythematosus. It seems…
Abstract Number: 1023 • 2019 ACR/ARP Annual Meeting
Neutrophils Are an Important Source of Microparticles in Lupus and Asymptomatic ANA+ Individuals
Carolina Muñoz-Grajales¹, Dennisse Bonilla ², Earl D. Silverman ³, Sindhu Johnson ⁴, Arthur Bookman ⁵, Zahi Touma ², Zareen Ahmad ⁶, Linda Hiraki ⁷ and Joan Wither ⁸, ¹University of Toronto, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁴Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁵University Health Network - Toronto Western Hospital, Toronto, Canada, ⁶Mount Sinai Hospital, Toronto, Canada, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Apoptotic microparticles (MPs) in the circulation of systemic lupus erythematosus (SLE) patients are enriched for nucleic acids and complexed with IgG (MP-IC), as compared…
Abstract Number: 1024 • 2019 ACR/ARP Annual Meeting
Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells
Sun Ah Kang¹, Jennifer Rogers ², Saira Sheikh ³, Megan Clowse ², Lisa Criscione-Schreiber ² and Barb Vilen ⁴, ¹University of NOrth Carolina at Chapel Hlil, Chapel Hill, NC, ²Duke University, Durham, ³University of North Carolina, Chapel Hill, NC, ⁴University of North Carolina CHapel Hill, Chapel Hill, NC
Background/Purpose: Impaired clearance of cell debris allows nuclear self-antigens such as DNA to accumulate, bind autoreactive IgG and form immune complexes (IgG-ICs) in SLE. We…
Abstract Number: 1025 • 2019 ACR/ARP Annual Meeting
Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity
Kieran Manion¹, Zahi Touma ², Dennisse Bonilla ², Dafna Gladman ³, Murray Urowitz ² and Joan Wither ⁴, ¹Krembil Research Institute, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: SLE is a chronic autoimmune disorder in which periods of relative disease inactivity are punctuated by flares that present with increased inflammation and tissue…
Abstract Number: 1026 • 2019 ACR/ARP Annual Meeting
Interferon Lambda Promotes Age-Associated B Cells
Jennifer Barnas¹, Nida Meednu ¹, Andrew McDavid ¹, Jennifer Albrecht ¹, Christopher Richardson ¹, R. John Looney ² and Jennifer Anolik ¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester
Background/Purpose: Age-associated B cells (ABC), defined as CD11c+ T-bet+ or CD11c+CD21-, represent a subset of B lymphocytes that are increased in systemic lupus erythematosus (SLE)…
Abstract Number: 1027 • 2019 ACR/ARP Annual Meeting
Characterization of Antibody Secreting Cells in Patients with Active Systemic Lupus Erythematosus
Weirong Chen¹, Sohee Hong ², Christopher Tipton ¹, Jennifer Hom ¹, Fabliha Anam ³, Eun-Hyung Lee ¹ and Iñaki Sanz ¹, ¹Emory University, Atlanta, GA, ²Emory Univeristy, Atlanta, ³Emory University, Atlanta
Background/Purpose: Systemic lupus erythematosus (SLE) is a severe systemic autoimmune disease in which multiple autoantibodies against nuclear, cytoplasmic and cell surface auto-antigens are produced by…
Abstract Number: 1028 • 2019 ACR/ARP Annual Meeting
Lupus Auto-antibodies Act as Positive Allosteric Modulators at GluN2A-containing NMDA Receptors to Induce Excitotoxicity and Spatial Memory Deficits
Kelvin Chan¹, Jacquelyn Nestor ², Tomas Huerta ², Czeslawa Kowal ², Patricio Huerta ², Bruce Volpe ², Betty Diamond ³ and Lonnie Wollmuth ¹, ¹Stony Brook University School of Medicine, Stony Brook, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Patients with Systemic lupus erythematosus (SLE) experience various peripheral and central nervous system manifestations including spatial memory impairment. A subset of auto-antibodies (DNRAbs) cross-react…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].